Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
